« Return to News | Drug Sponsors

AstraZeneca could be eyeing Cubist

Monday, May 23, 2011 02:16 PM

Speculation late last week suggested AstraZeneca could be eyeing an acquisition of Cubist Pharmaceuticals, according to a report in The Telegraph.

Lexington, Mass.-based Cubist sells an antibiotic called Cubicin, used to treat complex skin infections and the “superbug” MRSA. It is thought that U.S. sales of Cubicin could eventually top $1billion, and Cubist’s success in the tough antibiotics market has already marked it out as a possible acquisition target.

Last month, Cubist settled a patent dispute with Israeli drug maker Teva over Cubicin, which lessened the threat of generic competition. That prompted a number of analysts to suggest that Cubist could attract a suitor as other pharmaceutical companies, who are themselves facing oncoming generic competition, look to add new antibiotics to their portfolios.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.